The current status of adjuvant treatment for high-risk renal cell carcinoma

The treatment arms (1:1:1) received 54weeks of sunitinib 50mg per day orally throughout the first 4weeks of each 6week cycle, sorafenib 400mg twice per day orally throughout each cycle or placebo. Because of the poor tolerance and high discontinuation rates (44% in sunitinibarm and 45% in sorafenib...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2017-10, Vol.13 (23), p.2017-2020
Main Authors: H zal, Mutlu, endur, Mehmet AN, Bilgin, Burak, Ak nc, Muhammed Bülent, ener Dede, Didem, Yalç n, Bulent
Format: Article
Language:English
Subjects:
adjuvant treatment
Clinical trials
Histology
Kidney cancer
Metastasis
Pathogenesis
Patients
renal cell carcinoma
tyrosine kinase inhibitors
Vascular endothelial growth factor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment arms (1:1:1) received 54weeks of sunitinib 50mg per day orally throughout the first 4weeks of each 6week cycle, sorafenib 400mg twice per day orally throughout each cycle or placebo. Because of the poor tolerance and high discontinuation rates (44% in sunitinibarm and 45% in sorafenib arm), the starting dose was reduced sunitinib at 37.5mg daily and sorafenib at 400mg daily for one or two cycles and then up to original doses in the absence of significant side effects. [...]the investigators of S-TRAC emphasized the differences of study design and patient selection. [...]S-TRAC assessed DFS with blinded central review but the results of ASSURE processed by investigators (5 ,6). The patients received pazopanib or placebo for 1year after nephrectomy. Because of the high rates of discontinuation and tolerability problems starting dose of the drug was lowered from 800mg daily to 600mg daily after 403 patients had been treated.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0352